TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28751575

Group type: EXPERIMENTAL
Intervention: Intranasal lispro insulin (40 IU)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 25935345

Group type: EXPERIMENTAL
Intervention: Chimeric aspartate kinase BT3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical commercial feedback resistant aspartate kinase AKCfbr
Number of subjects: 0
Study: 24069451

Group type: EXPERIMENTAL
Intervention: Structured pro-active care by practice nurses (3 monthly review appointments over 2 years)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Structured pro-active care by practice nurses
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 41
Study: 21518460

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg once-daily
Number of subjects: 1647
Study: 19446387

Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Epinephrine (1 mg)
Number of subjects: 336
Study: 16397814

Group type: EXPERIMENTAL
Intervention: Cranberry juice (750 ml total, 250 ml cranberry juice + 500 ml mineral water)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (750 ml total, 750 ml placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cranberry juice (750 ml total, 750 ml cranberry juice)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (750 ml total, 250 ml placebo + 500 ml mineral water)
Number of subjects: 20
Study: 15558391

Group type: EXPERIMENTAL
Intervention: Harrison mirror‐image postural methods (mechanically assisted manipulation, opposite head posture exercise, opposite head translation posture traction)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study: 11763381

Group type: EXPERIMENTAL
Intervention: Finasteride (1 mg)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 236
Study: 8991295

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hypnotizability
Number of subjects: 64
Study: 8489204

Group type: EXPERIMENTAL
Intervention: 400 mg of zidovudine five times daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200 mg of zidovudine five times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo five times daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rerandomized to zidovudine treatment after week 16
Number of subjects: 40
Study: 3812604

Group type: EXPERIMENTAL
Intervention: Foundation Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICF/MR
Number of subjects: 0
Study: 29405229

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 26669200

Group type: EXPERIMENTAL
Intervention: Spleen-stomach needling
Number of subjects: 142

Group type: COMPARATOR
Intervention: Routine acupuncture (control)
Number of subjects: 142
Study: 23104677

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (HIIE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 21969650

Group type: EXPERIMENTAL
Intervention: Shared decision-making training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 61
Study: 19014840

Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 371
Study: 17149460

Group type: EXPERIMENTAL
Intervention: OxyArm (OA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nasal Cannula (NC)
Number of subjects: 25
Study: 12633191

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of fecal occult blood testing and sigmoidoscopy
Number of subjects: 0
Study: 10997423

Group type: EXPERIMENTAL
Intervention: Positive oral MR contrast media (Magnevist)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Negative oral MR contrast media (Abdoscan)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enteroclysis
Number of subjects: 50
Study: 9123628

Group type: EXPERIMENTAL
Intervention: Ultrasonographic scanning of the aorta
Number of subjects: 13500
Study: 8233262

Group type: EXPERIMENTAL
Intervention: GnRH agonist leuprolide acetate depot for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3545094

Group type: COMPARATOR
Intervention: Educational programme by community child health nurses, visited monthly for six months.
Number of subjects: 368
Study: 30672083

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 4038

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 4038
Study: 29921076

Group type: EXPERIMENTAL
Intervention: Continuous transfixion suture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 40
Study: 25990559

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 25214290

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (phloroglucinol)
Number of subjects: 79
Study: 23234302

Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 41
Study: 21150279

Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: JE-CV booster
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 17974538

Group type: EXPERIMENTAL
Intervention: Orthodontic toothbrush (OT) + Interproximal toothbrush (IT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Curved-bristle toothbrush (CBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orthodontic toothbrush (OT)
Number of subjects: 30
Study: 15734344

Group type: EXPERIMENTAL
Intervention: Raloxifene (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 28
Study: 12269682

Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control
Number of subjects: 255
Study: 9643144

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrostimulation (Amplipul's‐4 unit)
Number of subjects: 29
Study: 7989405

Group type: EXPERIMENTAL
Intervention: Fenbufen pretreatment (three days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg single oral dose)
Number of subjects: 8
Study: 2686576

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (mean dose 150 +/- 53 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Desipramine hydrochloride (mean dose 153 +/- 55 mg/d)
Number of subjects: 48
Study: 31987998

Group type: EXPERIMENTAL
Intervention: Global Signal Regression (GSR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Model-based physiological nuisance regression
Number of subjects: 38
Study: 31356376

Group type: EXPERIMENTAL
Intervention: Guidewire-assisted cannulation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Direct cannulation (Control)
Number of subjects: 90
Study: 28390501

Group type: EXPERIMENTAL
Intervention: Internet-based extinction therapy (IbET)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waiting-list condition (WL)
Number of subjects: 140
Study: 27542131

Group type: EXPERIMENTAL
Intervention: Social learning and cognitive behavioral therapy condition
Number of subjects: 185

Group type: COMPARATOR
Intervention: Education support condition
Number of subjects: 185
Study: 24602997

Group type: EXPERIMENTAL
Intervention: Placebo treatment (activation of a sham electrode) under continuous reinforcement (CRF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo treatment (activation of a sham electrode) under partial reinforcement (PRF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no conditioning)
Number of subjects: 60
Study: 22682023

Group type: EXPERIMENTAL
Intervention: Social support (measured by Oslo-3 Social Support Scale)
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Social support (as a mediator)
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Income
Number of subjects: 2387
Study: 20712749

Group type: EXPERIMENTAL
Intervention: Lamotrigine (up-titrated to 400 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Lithium (doses adjusted to obtain serum levels of 0.5-1.0 mmol/L)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 155
Study: 17344507

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg elemental Zn/d) for 12 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16389883

Group type: EXPERIMENTAL
Intervention: 95% of maximal 100m freestyle time (95% ITS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0% ITS (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 70% ITS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 8
Study: 12032024

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 90 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9754024

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac
Number of subjects: 106

Group type: COMPARATOR
Intervention: 0.1% fluorometholone
Number of subjects: 106
Study: 10203372

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate drink
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dialysis treatment
Number of subjects: 23
Study: 1884880

Group type: EXPERIMENTAL
Intervention: Miglitol (100 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6412267

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31837232

Group type: EXPERIMENTAL
Intervention: e‐cigarettes
Number of subjects: 36

Group type: COMPARATOR
Intervention: cigarettes
Number of subjects: 36

Group type: COMPARATOR
Intervention: cig‐a‐like devices
Number of subjects: 36

Group type: COMPARATOR
Intervention: fixed‐power tank devices
Number of subjects: 36
Study: 30638466

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (conventional bipolar device)
Number of subjects: 80
Study: 28986411

Group type: EXPERIMENTAL
Intervention: Virtual Leg Illusion (VLI) with synchronous visuotactile stimulation to the lower back
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Full Body Illusion (FBI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Virtual Leg Illusion (VLI)
Number of subjects: 40
Study: 27294869

Group type: EXPERIMENTAL
Intervention: Multifactorial weight reduction intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study: 27832555

Group type: EXPERIMENTAL
Intervention: Propofol at 0.2 µg/ml effect-site concentration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol at 0.4 µg/ml effect-site concentration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blood alcohol concentration of 0.05%
Number of subjects: 30
Study: 23974276

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone therapy (Omnadren 250) for 9 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 80

Group type: COMPARATOR
Intervention: MS+TDS- group
Number of subjects: 80
Study: 21679040

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100,000 norepinephrine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 36
Study: 19365786

Group type: EXPERIMENTAL
Intervention: Clarithromycin treatment for 3 months
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 144
Study: 16877720

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and etoposide (4 courses at 3-week intervals)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Paclitaxel (weekly for 24 weeks after initial treatment for those with objective response or stable disease)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 78
Study: 15526723

Group type: EXPERIMENTAL
Intervention: Sepsis (group S)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Septic shock (group SS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sepsis and septic shock (groups S and SS)
Number of subjects: 102
Study: 11424516

Group type: COMPARATOR
Intervention: YGD capsules (three capsules before each main meal for 10 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: YGD capsules (three capsules before each main meal for 45 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: YGD capsules (active treatment for 12 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: YGD capsules
Number of subjects: 44
Study: 10354964

Group type: EXPERIMENTAL
Intervention: OROS melatonin (1 x 110 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OROS melatonin (4 x 110 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OROS melatonin
Number of subjects: 12
Study: 7712308

Group type: EXPERIMENTAL
Intervention: UDCA (450 mg/day) for 6 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 101
Study: 2676224

Group type: EXPERIMENTAL
Intervention: Intraarterial cisplatin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cisplatin infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraarterial and intravenous cisplatin infusions
Number of subjects: 0
Study: 28870

Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (CZP) with 60 ml of water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clorazepate dipotassium (CZP) with 60 ml of magnesium aluminum hydroxide (Maalox)
Number of subjects: 10
Study: 31706144

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg daily
Number of subjects: 5522

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5522
Study: 27120190

Group type: EXPERIMENTAL
Intervention: Centrally placed resorbable screw and sheath (BioIntrafix)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Eccentrically placed resorbable interference screw (BioRCI) and two non‐resorbable staples
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Screw/sheath fixation
Number of subjects: 90
Study: 26305064

Group type: EXPERIMENTAL
Intervention: Rivastigmine (single oral dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rivastigmine (1-month treatment)
Number of subjects: 18
Study: 23136857

Group type: EXPERIMENTAL
Intervention: Positive emotional state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative emotional state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral affective state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific affective states
Number of subjects: 0
Study: 21508208

Group type: EXPERIMENTAL
Intervention: MEDAS (Mediterranean Diet Adherence Screener)
Number of subjects: 7146

Group type: EXPERIMENTAL
Intervention: MEDAS
Number of subjects: 7146

Group type: EXPERIMENTAL
Intervention: Higher PREDIMED score
Number of subjects: 7146

Group type: EXPERIMENTAL
Intervention: PREDIMED score
Number of subjects: 7146
Study: 19706137

Group type: EXPERIMENTAL
Intervention: Cell saving autotransfusion (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cell saving autotransfusion (Group B)
Number of subjects: 50
Study: 16690717

Group type: EXPERIMENTAL
Intervention: Nasal-only breathing (mouth taped)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral-only breathing (nose clip)
Number of subjects: 8
Study: 15296690

Group type: EXPERIMENTAL
Intervention: Theory-based personalized letter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored call delivered by community health care workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tailored letter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 11401930

Group type: EXPERIMENTAL
Intervention: Mobilization of endothelial progenitor cells (EPCs) in patients with acute myocardial infarction
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects with no evidence of cardiac ischemia
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patients with acute myocardial infarction
Number of subjects: 16
Study: 9368242

Group type: EXPERIMENTAL
Intervention: Fever duration <1 day
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Fever duration <2 days
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Fever duration 1-2 days
Number of subjects: 6680
Study: 9459317

Group type: EXPERIMENTAL
Intervention: Third generation oral contraceptives (OCs)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Other oral contraceptives (OCs)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no OCs)
Number of subjects: 201
Study: 2694767

Group type: EXPERIMENTAL
Intervention: Maintenance antipsychotic medication
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 49
Study: 798592

Group type: EXPERIMENTAL
Intervention: Asa foetida (0.1% alcoholic dilution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Asa foetida and Nux vomica (0.01% alcoholic dilution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31601389

Group type: EXPERIMENTAL
Intervention: CK‐MB elevation (≥5 × ULN)
Number of subjects: 13452

Group type: EXPERIMENTAL
Intervention: cTn elevation (≥35 × ULN)
Number of subjects: 13452

Group type: EXPERIMENTAL
Intervention: CK‐MB and cTn elevation
Number of subjects: 13452

Group type: EXPERIMENTAL
Intervention: CK‐MB ratio (≥10) post‐procedure
Number of subjects: 13452

Group type: EXPERIMENTAL
Intervention: cTn elevation
Number of subjects: 13452
Study: 28760751

Group type: EXPERIMENTAL
Intervention: Multitarget therapy (tacrolimus, 2‐3mg/d; mycophenolate mofetil, 0.50‐0.75 g/d; prednisone, 10mg/d)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg per day) plus prednisone (10 mg/d)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Multitarget therapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 206
Study: 24560740

Group type: EXPERIMENTAL
Intervention: Educational programme for nurses regarding health care during disasters
Number of subjects: 207
Study: 23760302

Group type: EXPERIMENTAL
Intervention: PVP with interventional tumor removal (ITR)
Number of subjects: 52

Group type: COMPARATOR
Intervention: PVP alone
Number of subjects: 52
Study: 20409520

Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular inflow occlusion
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Main portal vein inflow occlusion
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pringle maneuver
Number of subjects: 180
Study: 18999981

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 40
Study: 17009303

Group type: EXPERIMENTAL
Intervention: Leaf product
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pantegral design
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Small pad design
Number of subjects: 74

Group type: COMPARATOR
Intervention: Pouch designs
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Leaf designs
Number of subjects: 74
Study: 14716385

Group type: EXPERIMENTAL
Intervention: Information campaign led by the Norwegian Cancer Society since 1995
Number of subjects: 1000
Study: 11402254

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD-CHO)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Habitual diet (CTL)
Number of subjects: 5
Study: 9424001

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg p.o.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Metoclopramide 30 mg p.o.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Metoclopramide 60 mg p.o. (after dose increase)
Number of subjects: 23
Study: 8306001

Group type: EXPERIMENTAL
Intervention: Peribulbar block (PB)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Retrobulbar block (RB)
Number of subjects: 122
Study: 3743627

Group type: EXPERIMENTAL
Intervention: Soluble aspirin (1.2 g)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aspirin tablets (1.2 g)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Soluble aspirin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aspirin tablets
Number of subjects: 90
Study: 31287198

Group type: EXPERIMENTAL
Intervention: Magee scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (Oncotype DX)
Number of subjects: 0
Study: 29500541

Group type: EXPERIMENTAL
Intervention: 0.10% OCT rinse
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.15% OCT rinse
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.20% OCT rinse
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 90
Study: 26967681

Group type: EXPERIMENTAL
Intervention: Desipramine 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24751658

Group type: EXPERIMENTAL
Intervention: Plyometric training group (TG)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 76
Study: 22138847

Group type: EXPERIMENTAL
Intervention: Scaling and root planing and direct periodontal intrapocket application of 15% metronidazole‐based gel in two sites (>5 mm in depth)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Scaling and root planing (active control)
Number of subjects: 16
Study: 21090335

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Sishencong, Baihui, Shenting, etc.), once daily for 2 months.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/d), administered orally for 2 months.
Number of subjects: 300